Literature DB >> 21079052

Congenital epidermolysis bullosa acquisita: vertical transfer of maternal autoantibody from mother to infant.

Melissa L Abrams1, Aimee Smidt, Latanya Benjamin, Mei Chen, David Woodley, Anthony J Mancini.   

Abstract

BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a rare, chronic, autoimmune bullous dermatosis that is caused by autoantibodies against the noncollagenous terminus of the α chain of type VII collagen, resulting in decreased anchoring fibrils in the lamina densa. It classically presents with skin fragility and trauma-induced blisters that are particularly extensive over the distal aspect of the extremities and that heal with milia, dyspigmentation, and scarring, similar in presentation to dystrophic epidermolysis bullosa. Disease onset is typically in adulthood, although rare cases of childhood disease occur. To our knowledge, a case involving a neonate with congenital EBA has not yet been reported in the literature. We describe a newborn with transient EBA due to the passive transfer of maternal autoantibodies. OBSERVATIONS: A 2-day-old girl was evaluated for tense blisters and areas of denuded skin that had been present since birth. Her mother carried the diagnosis of EBA. The results of histopathologic analysis, immunofluorescence studies, and enzyme-linked immunosorbent assay confirmed the diagnosis of neonatal EBA. The patient improved with supportive therapy and has not required systemic intervention.
CONCLUSIONS: Autoimmune neonatal bullous skin disease caused by placental transfer of maternal IgG autoantibodies is rare. It has been reported in neonates born to mothers with pemphigus vulgaris, pemphigus foliaceus, and gestational pemphigoid. To our knowledge, congenital EBA has not been previously reported. Vertically acquired congenital autoimmune blistering disorders appear to be self-limited and resolve with supportive therapy, concomitant with the presumed clearance of maternal autoantibodies from the neonate's circulation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21079052     DOI: 10.1001/archdermatol.2010.317

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

1.  Epidermolysis bullosa acquisita.

Authors:  Denise Miyamoto; Juliana Olivieri Gordilho; Claudia Giuli Santi; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-06-11       Impact factor: 2.113

Review 2.  Bullous Diseases in Children: A Review of Clinical Features and Treatment Options.

Authors:  Brittney Schultz; Kristen Hook
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

Review 3.  IgG placental transfer in healthy and pathological pregnancies.

Authors:  Patricia Palmeira; Camila Quinello; Ana Lúcia Silveira-Lessa; Cláudia Augusta Zago; Magda Carneiro-Sampaio
Journal:  Clin Dev Immunol       Date:  2011-10-01

4.  Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases.

Authors:  Emilia Licarete; Susanne Ganz; Martin J Recknagel; Giovanni Di Zenzo; Takashi Hashimoto; Michael Hertl; Giovanna Zambruno; Gheorghe Hundorfean; Jonas Mudter; Markus F Neurath; Leena Bruckner-Tuderman; Cassian Sitaru
Journal:  BMC Immunol       Date:  2012-04-04       Impact factor: 3.615

5.  Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

Authors:  Ralf J Ludwig
Journal:  ISRN Dermatol       Date:  2013-07-15

6.  NEONATAL PEMPHIGUS IN AN INFANT BORN TO A MOTHER WITH PEMPHIGUS VULGARIS: A CASE REPORT.

Authors:  Adriana Amaral Carvalho; Dinamar Amador Dos Santos Neto; Mirelle Augusta Dos Reis Carvalho; Sabrina Jeane Prates Eleutério; Alessandra Rejane Ericsson de Oliveira Xavier
Journal:  Rev Paul Pediatr       Date:  2018-07-26

7.  Blister-inducing antibodies target multiple epitopes on collagen VII in mice.

Authors:  Kinga Csorba; Mircea Teodor Chiriac; Florina Florea; Miruna Georgiana Ghinia; Emilia Licarete; Andreea Rados; Alexandra Sas; Vlad Vuta; Cassian Sitaru
Journal:  J Cell Mol Med       Date:  2014-08-05       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.